“A revolutionary way of treating cancer” is the description one physician gives to the mechanism of a new drug, Kadcyla (Roche/Genentech), recently approved by the Food and Drug Administration for advanced breast cancer. Kadcyla targets tumor cells through a combination of the drug Herceptin and the chemotherapy drug DM1 (emtansine; ImmunoGen).
The drug will be used to treat about 20 percent of patients diagnosed with breast cancer, those with cancers that are HER2 positive.
Richard Pazdur, director of the Office of Hematology and Oncology Products at the FDA’s Center for Drug Evaluation and Research, notes that “Kadcyla delivers the drug to the cancer site to shrink the tumor, slow disease progression, and prolong survival.”
More information on this study can be found here.